Juno Launches With Competing Immunotherapy Programs
This article was originally published in Start Up
Executive Summary
The latest data from early cancer immunotherapy trials show patients in complete remission, reinforcing the field’s most-watched status. Juno Therapeutics is raising a war chest to capture programs from rival oncology research centers, but it doesn’t mean the competition has ended.